- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 249/12 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 249/12
Total number of patents in this class: 616
10-year publication summary
|
45
|
54
|
65
|
45
|
54
|
27
|
23
|
43
|
21
|
12
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 21313 |
22 |
| Theravance Biopharma R&D IP, LLC | 408 |
22 |
| Bayer Pharma AG | 1015 |
16 |
| Bayer AG | 3490 |
15 |
| Synta Pharmaceuticals Corp. | 146 |
14 |
| Ardea Biosciences, Inc. | 68 |
13 |
| UPL Limited | 629 |
12 |
| The Regents of the University of California | 20694 |
10 |
| King Faisal University | 931 |
10 |
| Yuhan Corporation | 241 |
10 |
| F. Hoffmann-La Roche AG | 7838 |
8 |
| The General Hospital Corporation | 4855 |
8 |
| FMC Corporation | 808 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 178 |
7 |
| The University of Queensland | 663 |
7 |
| Inflazome Limited | 84 |
7 |
| Tempest Therapeutics, Inc. | 27 |
7 |
| Cv6 Therapeutics (NI) Limited | 33 |
7 |
| Bayer Cropscience AG | 1847 |
6 |
| The Regents of the University of Michigan | 4970 |
6 |
| Other owners | 402 |